GenAI in healthcare
– friend or foe?

In In 2023, the market for GenAI in healthcare was worth $1.1bn, and this is expected to rise sharply to $17.2bn by 2032.

In this special feature on GenAI, we look at the race to explore and harness GenAI in healthcare, and how AI has graduated from being a procurer of efficiencies to seemingly an enabler of unimagined possibilities. We also focus on the importance of embracing the GenAI transformation with caution, emphasising that, despite the GenAI fervour, there is an acute need to prepare organisations to understand which specific tools they need and how to use them.

The articles in this special feature include interviews from 11 London, Day One Strategies, Havas Life London, Inizio Evoke, Inizio Ignite, Inizio Medical, Sprout and Veeva.